Prognostic impact of statins in heart failure with preserved ejection fraction 

Background: Heart failure (HF) with preserved ejection fraction (pEF) has lacked effective treatments for reducing mortality. However, previous studies have found an association between statin use and decreased mortality in patients with HFpEF. The aim of this study was to analyse whether statin the...

Descripción completa

Detalles Bibliográficos
Autores: Ortega-Hernández, Samanta, González-Sosa, Sonia, Conde Martel, Alicia, Trullàs, Joan Carles, Llàcer, Pau, Pérez-Silvestre, José, Arévalo-Lorido, José Carlos, Casado Cerrada, Jesús, Formiga Pérez, Francesc, Manzano, Luis, Lorenzo Villalba, Noel, Montero Pérez-Barquero, Manuel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/216356
Acceso en línea:https://hdl.handle.net/2445/216356
Access Level:acceso abierto
Palabra clave:Insuficiència cardíaca
Mortalitat
Agents antilipèmics
Heart failure
Mortality
Antilipemic agents
id ES_dbebd7d3d595e96ea0024d30d7811939
oai_identifier_str oai:recercat.cat:2445/216356
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prognostic impact of statins in heart failure with preserved ejection fraction Ortega-Hernández, SamantaGonzález-Sosa, SoniaConde Martel, AliciaTrullàs, Joan CarlesLlàcer, PauPérez-Silvestre, JoséArévalo-Lorido, José CarlosCasado Cerrada, JesúsFormiga Pérez, FrancescManzano, LuisLorenzo Villalba, NoelMontero Pérez-Barquero, ManuelInsuficiència cardíacaMortalitatAgents antilipèmicsHeart failureMortalityAntilipemic agentsBackground: Heart failure (HF) with preserved ejection fraction (pEF) has lacked effective treatments for reducing mortality. However, previous studies have found an association between statin use and decreased mortality in patients with HFpEF. The aim of this study was to analyse whether statin therapy is associated with a reduction in mortality in these patients and whether the effect differs according to the presence or absence of ischaemic heart disease (IHD). Methods: We analysed data from the National Registry of Heart Failure, a prospective study that included patients admitted for HF in Internal Medicine units nationwide. Patients with HFpEF were classified according to the use of statins, and the differences between the two groups were analysed. A multivariable analysis was performed using Cox regression to assess factors independently related to mortality. Results: A total of 2788 patients with HFpEF were included; 63% of them were women with a mean age of 80.1 (±7.8) years. The statin-treated group (40.2%) was younger, with better functional status, and had a more common diagnosis of vascular disease and lower frequency of atrial fibrillation. The most frequent aetiology of HF in both groups was the hypertensive one. Nevertheless, ischaemic HF was more common in those who received statins (24.8% vs. 9.6%; p < 0.001). Multivariable analysis showed lower mortality at the 1-year follow-up in statin-treated patients (OR: 0.74; 95%CI: 0.61-0.89; p = 0.002). This association was observed in patients without IHD (p < 0.001) but not in those with IHD (p = 0.11). Conclusions: Statins are associated with a decrease in total mortality in patients with HFpEF. This benefit occurs mainly in those without IHD.MDPI2024202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion15 p.application/pdfhttps://hdl.handle.net/2445/216356Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/jcm13195844Journal of Clinical Medicine, 2024, vol. 13, num.19https://doi.org/10.3390/jcm13195844cc-by (c) Ortega-Hernández, Samanta et al., 2024http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2163562026-05-29T05:05:01Z
dc.title.none.fl_str_mv Prognostic impact of statins in heart failure with preserved ejection fraction 
title Prognostic impact of statins in heart failure with preserved ejection fraction 
spellingShingle Prognostic impact of statins in heart failure with preserved ejection fraction 
Ortega-Hernández, Samanta
Insuficiència cardíaca
Mortalitat
Agents antilipèmics
Heart failure
Mortality
Antilipemic agents
title_short Prognostic impact of statins in heart failure with preserved ejection fraction 
title_full Prognostic impact of statins in heart failure with preserved ejection fraction 
title_fullStr Prognostic impact of statins in heart failure with preserved ejection fraction 
title_full_unstemmed Prognostic impact of statins in heart failure with preserved ejection fraction 
title_sort Prognostic impact of statins in heart failure with preserved ejection fraction 
dc.creator.none.fl_str_mv Ortega-Hernández, Samanta
González-Sosa, Sonia
Conde Martel, Alicia
Trullàs, Joan Carles
Llàcer, Pau
Pérez-Silvestre, José
Arévalo-Lorido, José Carlos
Casado Cerrada, Jesús
Formiga Pérez, Francesc
Manzano, Luis
Lorenzo Villalba, Noel
Montero Pérez-Barquero, Manuel
author Ortega-Hernández, Samanta
author_facet Ortega-Hernández, Samanta
González-Sosa, Sonia
Conde Martel, Alicia
Trullàs, Joan Carles
Llàcer, Pau
Pérez-Silvestre, José
Arévalo-Lorido, José Carlos
Casado Cerrada, Jesús
Formiga Pérez, Francesc
Manzano, Luis
Lorenzo Villalba, Noel
Montero Pérez-Barquero, Manuel
author_role author
author2 González-Sosa, Sonia
Conde Martel, Alicia
Trullàs, Joan Carles
Llàcer, Pau
Pérez-Silvestre, José
Arévalo-Lorido, José Carlos
Casado Cerrada, Jesús
Formiga Pérez, Francesc
Manzano, Luis
Lorenzo Villalba, Noel
Montero Pérez-Barquero, Manuel
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Insuficiència cardíaca
Mortalitat
Agents antilipèmics
Heart failure
Mortality
Antilipemic agents
topic Insuficiència cardíaca
Mortalitat
Agents antilipèmics
Heart failure
Mortality
Antilipemic agents
description Background: Heart failure (HF) with preserved ejection fraction (pEF) has lacked effective treatments for reducing mortality. However, previous studies have found an association between statin use and decreased mortality in patients with HFpEF. The aim of this study was to analyse whether statin therapy is associated with a reduction in mortality in these patients and whether the effect differs according to the presence or absence of ischaemic heart disease (IHD). Methods: We analysed data from the National Registry of Heart Failure, a prospective study that included patients admitted for HF in Internal Medicine units nationwide. Patients with HFpEF were classified according to the use of statins, and the differences between the two groups were analysed. A multivariable analysis was performed using Cox regression to assess factors independently related to mortality. Results: A total of 2788 patients with HFpEF were included; 63% of them were women with a mean age of 80.1 (±7.8) years. The statin-treated group (40.2%) was younger, with better functional status, and had a more common diagnosis of vascular disease and lower frequency of atrial fibrillation. The most frequent aetiology of HF in both groups was the hypertensive one. Nevertheless, ischaemic HF was more common in those who received statins (24.8% vs. 9.6%; p < 0.001). Multivariable analysis showed lower mortality at the 1-year follow-up in statin-treated patients (OR: 0.74; 95%CI: 0.61-0.89; p = 0.002). This association was observed in patients without IHD (p < 0.001) but not in those with IHD (p = 0.11). Conclusions: Statins are associated with a decrease in total mortality in patients with HFpEF. This benefit occurs mainly in those without IHD.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/216356
url https://hdl.handle.net/2445/216356
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/jcm13195844
Journal of Clinical Medicine, 2024, vol. 13, num.19
https://doi.org/10.3390/jcm13195844
dc.rights.none.fl_str_mv cc-by (c) Ortega-Hernández, Samanta et al., 2024
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Ortega-Hernández, Samanta et al., 2024
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 15 p.
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421721339035648
score 15.812429

Similares en LA Referencia